Bimekizumab is a medicine used to treat psoriasis, some kinds of arthritis, and a painful skin condition called hidradenitis suppurativa. It is given as a shot under the skin. It works by blocking two proteins that cause swelling and irritation in the body.
Every report comes from a Lived member, sent anonymously.
Have you tried Bimzelx (Bimekizumab) for Psoriasis?
Bimekizumab, sold as Bimzelx, is a prescription biologic medicine given by injection. It is approved for adults with five long-term inflammatory conditions of the skin and joints. For moderate to severe plaque psoriasis, it is meant for people whose psoriasis calls for treatment that works throughout the body (pills or injections) or for light therapy, rather than creams alone. It is also approved for active psoriatic arthritis, the joint inflammation that can come with psoriasis, and for two forms of inflammatory arthritis of the spine: ankylosing spondylitis, and non-radiographic axial spondyloarthritis, which causes similar back pain and stiffness without the damage that shows up on x-rays but with measurable signs of inflammation. It is also approved for moderate to severe hidradenitis suppurativa (HS), a chronic skin disease that causes painful, boil-like lumps where skin rubs together, such as the armpits and groin. The lumps can break open into draining abscesses and leave scarring and tunnels under the skin. Bimzelx is not approved for children.
Interleukin-17A and interleukin-17F (IL-17A and IL-17F) are signaling proteins the immune system uses to switch on inflammation. In psoriasis, psoriatic arthritis, spinal arthritis and HS, this signaling is overactive and helps keep skin plaques, swollen joints or painful nodules going. Bimekizumab is a monoclonal antibody, a lab-made protein designed to latch onto a specific target. It binds both IL-17A and IL-17F and stops them from reaching their receptors on cells, which reduces the release of other inflammatory signals downstream. Because these proteins are also part of the body's normal immune defenses, turning them down reduces inflammation at the cost of a higher chance of some infections.
Bimzelx is injected under the skin with a prefilled syringe or an autoinjector pen, in the thigh, abdomen or back of the upper arm. The first injection is done with a healthcare professional so the person can learn the technique; after that, most people inject at home. A dose of 320 mg is given either as one larger injection or as two 160 mg injections at different spots. Injections should not go into skin that is tender, bruised, red, hard or covered by psoriasis, or within 2 inches of the navel. The schedule depends on the condition. For plaque psoriasis, 320 mg is given every 4 weeks for the first 16 weeks and then every 8 weeks; people weighing 120 kg (about 265 pounds) or more may stay on every 4 weeks. For psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis, the dose is 160 mg every 4 weeks, although people who also have moderate to severe psoriasis follow the psoriasis schedule. For HS, 320 mg is given every 2 weeks for the first 16 weeks and then every 4 weeks. Before the first dose, people are tested for tuberculosis (TB) and have blood tests of liver function, and any needed vaccines are brought up to date. The pens and syringes are kept in the refrigerator in their carton and left out for 30 to 45 minutes to reach room temperature before injecting. They can be kept at room temperature for one stretch of up to 30 days, but not returned to the fridge. If a dose is missed, inject it as soon as you remember and then return to the regular schedule.
The most common side effects are colds and other upper respiratory infections, headache and reactions where the shot was given. Yeast and fungal infections are a distinctive trade-off of blocking IL-17. Oral thrush (candidiasis), which causes white patches or soreness in the mouth, affected about 9 in 100 people with psoriasis in the first 16 weeks of trials, compared with none on placebo. Athlete's foot, vaginal yeast infections and other fungal skin infections also occurred. Other reported effects included cold sores, stomach bugs and diarrhea, urinary tract infections, acne and inflamed hair follicles, and tiredness. These are usually worth reporting so they can be treated rather than simply waited out. Bimzelx can also make serious infections more likely. Call the care team right away for fever, sweats or chills, a cough or shortness of breath that will not settle, blood in phlegm, unexplained weight loss, warm, red or painful skin sores, or burning when urinating. Treatment is usually paused until an infection clears. Liver enzyme levels rose in some people in trials and came back down, in some while they kept taking it and in others after it was stopped. Hold the next dose and call the prescriber right away for pain on the upper right side of the abdomen, unusual tiredness, loss of appetite, nausea or vomiting, dark urine, pale stools, or yellowing of the skin or eyes.
Bimzelx carries a warning about suicidal thoughts and behavior. In trials for psoriasis and HS, slightly more people taking it reported suicidal thoughts than people on placebo (about 2 in 100 compared with under 1 in 100), although a direct cause has not been proven. People with a history of severe depression or suicidal thoughts should weigh this with their prescriber before starting. New or worsening depression, anxiety or other mood changes should be reported to the prescriber promptly, and anyone having thoughts of suicide should get medical help right away or call the 988 Suicide and Crisis Lifeline. It is not used during an active infection, and people with active TB should not take it. Latent (inactive) TB is treated before starting. It is also generally avoided in people with active inflammatory bowel disease (Crohn's disease or ulcerative colitis), because IL-17 blockers can trigger new cases or flares; new or worsening stomach pain or diarrhea should be reported. People with acute liver disease or cirrhosis should avoid it because of a higher risk of serious liver injury. Live vaccines (made from weakened forms of a germ) should be avoided during treatment, so tell anyone giving a vaccine that you take Bimzelx. Starting or stopping it can shift the levels of some medicines that have a narrow safe range, such as the blood thinner warfarin or the immune-suppressing drug cyclosporine, so extra checks may be needed. There is too little information to know whether Bimzelx is safe in pregnancy. Antibodies like it cross the placenta, mostly late in pregnancy, so a baby exposed in the womb may need live vaccines delayed for at least 4 months after birth. Whether it passes into breast milk is not known.
In psoriasis, improvement is often fast and substantial. In the main trials, about three in four people had at least 75% clearer skin by week 4. By week 16, 85% to 91% had at least 90% clearer skin and roughly 6 to 7 in 10 were completely clear, with scalp psoriasis responding as well. In psoriatic arthritis, the change is steadier. After 16 weeks, about 44% of people had at least a 50% improvement on a standard score that combines tender and swollen joint counts, pain and daily function, compared with 7% to 10% on placebo. Results were similar in people whose arthritis had not responded to TNF blockers, an older group of biologics that block a different inflammatory signal called tumor necrosis factor. For the spinal forms of arthritis, comparisons across trials suggest it works about as well as most other biologic options. In HS, the goal is fewer painful lumps and abscesses rather than complete clearing. At 16 weeks, about half of people taking it every 2 weeks had their lump and abscess count cut by at least half without new draining tunnels, compared with about 30% on placebo, and responses held or improved through the first year. Bimzelx is a long-term treatment that controls these conditions rather than curing them. When psoriasis trial participants who had responded stopped treatment, half had lost their 90% clearance within about 6 months, though most regained clear or almost clear skin within 12 weeks of restarting. Ongoing care includes periodic liver blood tests and attention to infections, mood and any symptoms of TB.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Bimzelx (Bimekizumab), what you've noticed, or ask the community a question.